Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 16/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15703303 | 0.99 | PARP1 (0.62) | PARP1SIGMAR1RENKDRCNR2 | |
| SCHEMBL14647181 | 0.96 | PARP1 (0.56) | PARP1SIGMAR1KDRCNR2 | |
| SCHEMBL14647128 | 0.91 | PARP1 (0.51) | PARP1CNR2 | |
| SCHEMBL14647268 | 0.84 | PARP1 (0.65) | PARP1 | |
| SCHEMBL14647212 | 0.83 | PARP1 (0.61) | PARP1KDRCNR2 | |
| SCHEMBL14647177 | 0.82 | PARP1 (0.48) | PARP1 | |
| SCHEMBL14647161 | 0.81 | MGLL (0.52) | PARP1 | |
| SCHEMBL14647172 | 0.81 | PARP1 (0.54) | PARP1 | |
| SCHEMBL14647129 | 0.81 | L3MBTL3 (0.53) | PARP1 | |
| SCHEMBL15703236 | 0.80 | PARP1 (0.50) | PARP1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2733144-B1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO LTD (JP) | 2016-01-06 | — | — | EP | claimed |
| CN-103703002-A | Novel compound having parp inhibitory activity | SANTEN PHARMACEUTICAL CO LTD | 2014-04-02 | — | — | CN | claimed |
| CN-103703002-B | There is PARP and suppress active new compound | SANTEN PHARMACEUTICAL CO.,LTD. (JP) | 2016-05-11 | — | — | CN | disclosed |
| US-9062061-B2 | Compound having PARP inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-9062061-B2 | Compound having PARP inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2015-06-23 | — | — | US | disclosed |
| US-20140243320-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
| US-20140243320-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-08-28 | — | — | US | disclosed |
| EP-2733144-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | Santen Pharmaceutical Co., Ltd (JP) | 2014-05-21 | — | — | EP | disclosed |
| CN-103703002-A | Novel compound having parp inhibitory activity | SANTEN PHARMACEUTICAL CO LTD | 2014-04-02 | — | — | CN | disclosed |
| WO-2013008872-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | 参天製薬株式会社 (JP) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243320-A1 | NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY | PARP1, PARP11, PARP2 | PARP1 1/4885SIGMAR1 1466/4885REN 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.